Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
39
XBIT Quote, Financials, Valuation and Earnings
Last price:
$2.50
Seasonality move
:
9.81%
Day range:
$2.45 - $2.49
52-week range:
$2.09 - $4.67
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
22.19x
P/B ratio:
0.45x
Volume:
32.6K
Avg. volume:
68.7K
1-year change:
-45.61%
Market cap:
$75M
Revenue:
--
EPS (TTM):
-$0.96
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, XBiotech, Inc. has 631.71% upside to fair value with a price target of -- per share.
XBIT vs. S&P 500
-
Over the past 5 trading days, XBiotech, Inc. has underperformed the S&P 500 by -1.55% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
XBiotech, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
XBiotech, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter XBiotech, Inc. reported revenues of --.
Earnings Growth
-
XBiotech, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter XBiotech, Inc. reported earnings per share of -$0.20.
Enterprise value:
-72.4M
EV / Invested capital:
-0.43x
Price / LTM sales:
22.19x
EV / EBIT:
--
EV / Revenue:
-16.68x
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
3.03x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.7M
Return On Assets:
-15.48%
Net Income Margin (TTM):
--
Return On Equity:
-16.39%
Return On Invested Capital:
-16.03%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $300K | -- | -- | -- | -- | |
| Gross Profit | -$1.5M | -$1.7M | -$1.7M | -$439K | -$427K | |
| Operating Income | -$37.1M | -$42.3M | -$34.7M | -$7.9M | -$6M | |
| EBITDA | -$35.3M | -$40.6M | -$32.9M | -$7.5M | -$5.6M | |
| Diluted EPS | -$0.76 | -$1.07 | -$0.96 | -$0.16 | -$0.20 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $249.7M | $223.4M | $204.4M | $185M | $149M | |
| Total Assets | $279.5M | $250.8M | $229.6M | $209.9M | $172.4M | |
| Current Liabilities | $3.9M | $3.6M | $5.3M | $16M | $3.6M | |
| Total Liabilities | $5.4M | $6M | $6.9M | $17.7M | $5.3M | |
| Total Equity | $274.2M | $244.8M | $222.7M | $192.1M | $167.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$12.6M | -$27.9M | -$23.5M | -$5.8M | -$4.3M | |
| Cash From Investing | $57.7M | -$1.3M | -$339K | -$338K | -$110K | |
| Cash From Financing | -$9K | $10.2M | -$10M | $64K | -- | |
| Free Cash Flow | -$13M | -$29.2M | -$23.8M | -$6.2M | -$4.4M | |
XBIT
Sector
Market Cap
$75M
$28.1M
Price % of 52-Week High
52.68%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
2.43%
-1.49%
1-Year Price Total Return
-45.33%
-17.13%
Beta (5-Year)
0.779
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.47
200-day SMA
Sell
Level
$2.83
Bollinger Bands (100)
Sell
Level
2.36 - 2.98
Chaikin Money Flow
Buy
Level
578
20-day SMA
Buy
Level
$2.45
Relative Strength Index (RSI14)
Buy
Level
51.13
ADX Line
Sell
Level
17.21
Williams %R
Neutral
Level
-78.5714
50-day SMA
Buy
Level
$2.44
MACD (12, 26)
Buy
Level
0.65
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
41.5K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.913)
Buy
CA Score
(Annual)
Level (0.6599)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (1.9193)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.
Stock Forecast FAQ
In the current month, XBIT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The XBIT average analyst price target in the past 3 months is --.
-
Where Will XBiotech, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that XBiotech, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About XBiotech, Inc.?
Analysts are divided on their view about XBiotech, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that XBiotech, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is XBiotech, Inc.'s Price Target?
The price target for XBiotech, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is XBIT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for XBiotech, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of XBIT?
You can purchase shares of XBiotech, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase XBiotech, Inc. shares.
-
What Is The XBiotech, Inc. Share Price Today?
XBiotech, Inc. was last trading at $2.50 per share. This represents the most recent stock quote for XBiotech, Inc.. Yesterday, XBiotech, Inc. closed at $2.48 per share.
-
How To Buy XBiotech, Inc. Stock Online?
In order to purchase XBiotech, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get XBIT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
XBIT
Sector
P/E ratio
--
23.89x
PEG ratio
-0.03x
-0.01x
P/B ratio
0.45x
1.81x
Price / LTM sales
22.19x
1.59x
Growth Metrics
XBIT
Sector
Revenue growth
--
4.62%
Earnings growth
-19.75%
11.06%
Revenue (5-year growth)
--
6.5%
Earnings forecast
--
-$0.21
Profitability
XBIT
Sector
Profitability FY 2024
-$1.7M
$3.6M
Return on invested capital
-16.03%
-31.84%
Return on assets
-15.48%
-27.96%
Return on equity
-16.39%
-37.63%
Earnings Date
Last Earnings Date
Mar
14
Next Earnings Date
Dec
25
Estimated Next Earnings Date
Mar
26
Balance Sheet
XBIT
Sector
Total cash
$147.4M
$26.4M
Short term investments
--
$25.7M
Total assets
$199.1M
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
